⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ALKS News
Alkermes Inc. plc
The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1
businesswire.com
ALKS
Sleep as a Window into Early Stages of Alzheimer's Pathophysiology: Implications for Clinical Development, Upcoming Webinar Hosted by Xtalks
prnewswire.com
BCRX
ALKS
LLY
BIIB
ABBV
Form 8-K
sec.gov
ALKS
Global Neurodegenerative Disease Market is Expected to Showcase Significant Growth at a CAGR of ~6% by 2034 | DelveInsight
globenewswire.com
NVO
LLY
BMY
AXSM
JNJ
SNY
BIIB
ABBV
MRK
REGN
GILD
AMGN
AZN
TEVA
BHC
ALKS
VRTX
SRPT
CRIS
NTLA
EDIT
INCY
ACAD
ALNY
CYTK
IONS
EXAS
IDXX
VNDA
SUPN
RGNX
XOM
CVAC
BNTX
ARCT
MRNA
NBIX
ADPT
AVXL
IMUX
PRGS
RDNT
CRDF
ADSK
ANAB
ATRC
CLDX
CPRX
ESPR
EXEL
FGEN
GALT
GRFS
HRMY
IGC
INSM
KODK
LAKE
LCTX
LEXX
LPCN
MESO
MITK
MNKD
MSFT
MYGN
NEO
NVCR
NXPI
OCGN
OMER
ORCL
PACB
PFE
PLRX
PRGO
PSNL
PTGX
QGEN
RARE
ROST
RVMD
SEIC
SIGA
SMCI
SNOW
SOFI
SPRO
TGTX
TNDM
TXG
ULTA
VEEV
VKTX
VRNS
WVE
XRAY
ZBRA
ZNTL
Form 8-K/A
sec.gov
ALKS
Amylin Analogs and Combination Therapies Clinical Trial Landscape Expands as 15+ Leading Companies Accelerate Drug Development | DelveInsight
globenewswire.com
AZN
LLY
NVO
PFE
AMGN
BMY
JNJ
REGN
VKTX
ZETA
CRSP
IONS
AXSM
MRK
GSK
SNY
IMUX
BMEA
ALKS
ALT
AARD
NOV
CARM
CRIS
LPCN
GILD
REG
SPRO
ABSI
ALZN
ANVS
BV
ARCL
ACIU
Form 8-K
sec.gov
ALKS
Alkermes plc Reports Second Quarter 2026 Financial Results
businesswire.com
ALKS
Substance Use Disorder Treatment Market to Reach $14.6 Billion by 2030, Driven by Growing Patient Populations and Policy Reform
globenewswire.com
IVZ
ALKS
Mentari Therapeutics Appoints Industry Veteran Greg Divis as Chief Executive Officer
prnewswire.com
AVDL
ALKS
MRK
SNY